Prenatal DNA Sequencing Market Report 2026

Prenatal DNA Sequencing Market Overview

• Prenatal DNA Sequencing market size has reached to $2.82 billion in 2025 • Expected to grow to $6.09 billion in 2030 at a compound annual growth rate (CAGR) of 16.6% • Growth Driver: Higher Birth Rate Is Anticipated To Fuel The Prenatal DNA Sequencing Market • Market Trend: Strategic Collaborations Drive Innovation In The Prenatal DNA Sequencing Market • North America was the largest region in 2025.

What Is Covered Under Prenatal DNA Sequencing Market?

Prenatal DNA sequencing refers to a method of sequencing the DNA of an unborn baby by using the blood sample from the mother that helps to reveal the full genetic code of the unborn baby. It is used to detect fetal disorders or diseases. The main types of prenatal DNA sequencing are genetic diseases and nonhereditary diseases. Genetic diseases refer to any disorder or disease that is caused by mutations in one or more genes. DNA sequencing helps to determine whether a gene contains a mutation that causes a disorder. It is used in various applications such as hemophilia, down syndrome, cystic fibrosis, autism, DiGeorge syndrome, AIDS, cancer, and others by academic research, clinical research, hospitals and clinics, pharmaceutical and biotechnology companies, and other users.

What Is The Prenatal DNA Sequencing Market Growth Forecast?

The prenatal dna sequencing market size is expected to see rapid growth in the next few years. It will grow to $6.09 billion in 2030 at a compound annual growth rate (CAGR) of 16.6%. The growth in the forecast period can be attributed to increasing demand for comprehensive prenatal diagnostics, rising investments in precision medicine research, expansion of clinical sequencing applications, growing use of ai-driven genomic interpretation, increasing collaboration between healthcare and biotech firms. Major trends in the forecast period include increasing adoption of cell-free fetal dna sequencing, rising use of whole-genome prenatal sequencing, growing integration of bioinformatics platforms, expansion of high-accuracy sequencing technologies, enhanced focus on rare disease detection.

Global Prenatal DNA Sequencing Market Segmentation

1) By Type: Genetic Diseases, Nonhereditary Diseases 2) By Application: Hemophilia, Down Syndrome, Cystic Fibrosis, Autism, DiGeorge Syndrome, Inherited Immunodeficiency Disorders, Cancer, Other Applications 3) By End User: Academic Research, Clinical Research, Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Other End Users Subsegments: 1) By Genetic Diseases: Monogenic Disorders, Chromosomal Abnormalities 2) By Nonhereditary Diseases: Infectious Diseases, Maternal Health Conditions

What Is The Driver Of The Prenatal DNA Sequencing Market?

The higher birth rate is expected to propel the growth of the prenatal DNA sequencing market going forward. Birth rate is the number of live births per 1,000 people in a given population within a specified period, usually expressed on an annual basis. Prenatal DNA sequencing aids in identifying genetic abnormalities in unborn fetuses, contributing to informed reproductive decisions during birth through selective interventions. For instance, in January 2023, according to a report published by the Centers for Disease Control and Prevention, a US-based national public health organization, the United States witnessed a 1% increase in registered births, totaling 3,664,292, compared to the previous year. Therefore, the higher birth rate is driving the prenatal DNA sequencing industry.

Key Players In The Global Prenatal DNA Sequencing Market

Major companies operating in the prenatal dna sequencing market are Agilent Technologies Inc, BGI Group, F Hoffmann La Roche Ltd, Illumina Inc, Laboratory Corporation Of America Holdings, Natera Inc, Myriad Genetics Inc, Invitae Corporation, PerkinElmer Inc, Macrogen Inc, Pacific Biosciences Of California Inc, Genewiz LLC, Oxford Nanopore Technologies Limited, Thermo Fisher Scientific Inc, Eurofins LifeCodexx AG, GeneDx Inc, Genoma SA, Helix OpCo LLC, Igenomix SL, Integrated DNA Technologies Inc, Roche Diagnostics GmbH, Berry Genomics Co Ltd

Global Prenatal DNA Sequencing Market Trends and Insights

Major companies operating in the prenatal DNA sequencing market are adopting a strategic partnership approach to enhance technology integration and expand market reach. A strategic partnership typically refers to a collaborative relationship between two or more organizations where they combine their resources, expertise, and efforts to achieve common goals or objectives. For instance, in December 2023, BillionToOne, a US-based precision diagnostics company, partnered with a Johnson & Johnson company, a US-based pharmaceutical company, for the AZALEA Phase 3 clinical trial of nipocalimab. The trial focuses on pregnancies at risk for severe hemolytic disease of the fetus and newborn (HDFN). BTO will provide its UNITY Fetal Antigen Non-invasive Prenatal Test (UNITY Fetal Antigen CTA) to screen and determine the eligibility of participants. HDFN is a rare condition caused by blood type incompatibility between the pregnant individual and the fetus, potentially leading to life-threatening anemia.

What Are Latest Mergers And Acquisitions In The Prenatal DNA Sequencing Market?

In December 2023, BillionToOne (BTO), a US-based molecular diagnostics company specializing in noninvasive prenatal testing, collaborated with Janssen Research & Development, LLC, to enhance prenatal precision to advance safer and more effective fetal-maternal care. The collaboration aims to improve the selection of pregnant individuals for HDFN-focused clinical trials by using UNITY’s advanced prenatal DNA screening to accurately determine fetal antigen status. Janssen Research & Development, LLC is a US-based pharmaceutical company.

Regional Outlook

North America was the largest region in the prenatal DNA sequencing market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Prenatal DNA Sequencing Market?

The prenatal DNA sequencing market includes revenues earned by entities by providing services such as prenatal next-generation sequencing, whole genome sequencing, DNA extraction, DNA fragmentation, and data collection and sequence analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Prenatal DNA Sequencing Market Report 2026?

The prenatal dna sequencing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the prenatal dna sequencing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.